In this study the Authors developed a Therapeutic Escalation Score (TES) to identify children at low risk of early escalation after initiating moderate-efficacy therapy (MET).
TES incorporated age, year of treatment initiation, Expanded Disability Status Scale score, prior-year relapses, brain lesion location, and T2 spinal cord lesions. A TES threshold of 1.34 stratified patients by 1-year escalation risk.
They concluded that TES is a baseline-only prognostic tool using routine clinical and MRI data to identify children with MS unlikely to require early escalation after MET initiation.
See the full text here: https://journals.sagepub.com/doi/10.1177/13524585261446829